JW (Cayman) Therapeutics Co. Ltd (HKG:2126)
Hong Kong · Delayed Price · Currency is HKD 1.600
+0.010 (0.63%)
Jun 18, 2026, 11:18 AM HKT
HKG:2126 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 283.65 | 158.22 | 173.86 | 145.7 | 30.8 |
| 283.65 | 158.22 | 173.86 | 145.7 | 30.8 | |
Revenue Growth (YoY) | 79.28% | -9.00% | 19.32% | 373.11% | - |
Cost of Revenue | 110.57 | 80.9 | 85.64 | 86.95 | 21.75 |
Gross Profit | 173.08 | 77.32 | 88.22 | 58.76 | 9.05 |
Selling, General & Admin | 232.84 | 260.48 | 253.24 | 370.64 | 372.25 |
Research & Development | 188.38 | 282.99 | 413.62 | 407.82 | 414.4 |
Other Operating Expenses | -4.25 | -7.12 | -8.5 | -22.53 | -5.89 |
Operating Expenses | 416.96 | 536.35 | 658.37 | 755.93 | 780.76 |
Operating Income | -243.88 | -459.03 | -570.15 | -697.18 | -771.72 |
Interest Expense | -11.43 | -12.22 | -12.42 | -6.79 | -2.69 |
Interest & Investment Income | 20.96 | 28.43 | 34.03 | 16.54 | 8.3 |
Currency Exchange Gain (Loss) | 36.99 | -15.6 | -37.32 | -158.54 | 14.84 |
Other Non Operating Income (Expenses) | - | - | - | - | 51.15 |
EBT Excluding Unusual Items | -197.37 | -458.42 | -585.86 | -845.97 | -700.12 |
Gain (Loss) on Sale of Assets | - | - | -0.93 | -0.17 | -0.12 |
Asset Writedown | -354.86 | -132.26 | -181.21 | - | - |
Other Unusual Items | - | 0.05 | - | - | -2.09 |
Pretax Income | -552.23 | -590.62 | -768 | -846.14 | -702.33 |
Income Tax Expense | 3.07 | - | - | - | - |
Net Income | -555.29 | -590.62 | -768 | -846.14 | -702.33 |
Net Income to Common | -555.29 | -590.62 | -768 | -846.14 | -702.33 |
Shares Outstanding (Basic) | 416 | 414 | 412 | 410 | 400 |
Shares Outstanding (Diluted) | 416 | 414 | 412 | 410 | 400 |
Shares Change (YoY) | 0.52% | 0.51% | 0.35% | 2.59% | 203.07% |
EPS (Basic) | -1.34 | -1.43 | -1.87 | -2.06 | -1.76 |
EPS (Diluted) | -1.34 | -1.43 | -1.87 | -2.06 | -1.76 |
Free Cash Flow | -78.23 | -338.67 | -410.83 | -613.6 | -634.29 |
Free Cash Flow Per Share | -0.19 | -0.82 | -1.00 | -1.50 | -1.59 |
Gross Margin | 61.02% | 48.87% | 50.74% | 40.33% | 29.37% |
Operating Margin | -85.98% | -290.13% | -327.94% | -478.49% | -2505.82% |
Profit Margin | -195.76% | -373.30% | -441.74% | -580.73% | -2280.51% |
Free Cash Flow Margin | -27.58% | -214.05% | -236.30% | -421.13% | -2059.57% |
EBITDA | -181.27 | -391.09 | -492.69 | -629.53 | -738.7 |
EBITDA Margin | -63.91% | -247.18% | -283.39% | - | - |
D&A For EBITDA | 62.61 | 67.95 | 77.46 | 67.65 | 33.01 |
EBIT | -243.88 | -459.03 | -570.15 | -697.18 | -771.72 |
EBIT Margin | -85.98% | -290.13% | - | - | - |
Advertising Expenses | 107.03 | 97.18 | 48.39 | 77.39 | 70.12 |